Skip to main content
Terug
ZLDPF logo

Zealand Pharma A/S

Datakwaliteit: 100%
Oversold
ZLDPF
OTC Healthcare Biotechnology
€ 40,99
€ 0,00 (0,00%)
Marktkapitalisatie: 2,89B
Dagbereik
€ 40,99 € 42,08
52-Weeksbereik
€ 35,93 € 83,52
Volume
125
50D / 200D Gem.
€ 58,21 / € 65,85
Vorige Slotkoers
€ 40,99

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,5 0,4
P/B 0,2 2,9
ROE % 55,0 3,8
Net Margin % 70,1 3,9
Rev Growth 5Y % 136,8 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 136,77% annually over 5 years — strong growth
ROE of 55,01% indicates high profitability
Net margin of 70,05% shows strong profitability
Debt/Equity of 0,03 — conservative balance sheet
Generating 6,48B in free cash flow
P/E of 0,45 — trading at a low valuation

Groei

Revenue Growth (5Y)
136,77%
Revenue (1Y)14565,56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
55,01%
ROIC35,04%
Net Margin70,05%
Op. Margin77,66%

Veiligheid

Debt / Equity
0,03
Current Ratio23,57
Interest Coverage189,81

Waardering

P/E Ratio
0,45
P/B Ratio0,20
EV/EBITDA-0,17
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 14565,56% Revenue Growth (3Y) 417,89%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 136,77% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9,19B Net Income (TTM) 6,44B
ROE 55,01% ROA 39,21%
Gross Margin 99,69% Operating Margin 77,66%
Net Margin 70,05% Free Cash Flow (TTM) 6,48B
ROIC 35,04% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 23,57
Interest Coverage 189,81 Dividend Yield 0,00%
Valuation
P/E Ratio 0,45 P/B Ratio 0,20
P/S Ratio 0,31 PEG Ratio -0,01
EV/EBITDA -0,17 Dividend Yield 0,00%
Market Cap 2,89B Enterprise Value -1,19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,19B 62,69M 342,79M 103,99M 292,57M
Net Income 6,44B -1,08B -703,74M -965,61M -1,02B
EPS (Diluted) 90,04 -16,24 -12,44 -20,90 -23,75
Gross Profit 9,17B 54,82M 323,61M 73,28M 173,75M
Operating Income 7,14B -1,27B -572,24M -816,60M -1,05B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,42B 9,51B 1,98B 1,54B 2,07B
Total Liabilities 1,63B 888,86M 387,15M 723,90M 1,14B
Shareholders' Equity 14,80B 8,62B 1,59B 815,91M 927,80M
Total Debt 484,88M 391,76M 119,23M 443,47M 787,43M
Cash & Equivalents 4,57B 480,30M 449,31M 1,07B 1,13B
Current Assets 15,63B 8,53B 1,78B 1,32B 1,72B
Current Liabilities 663,46M 403,47M 284,58M 195,49M 334,32M

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#152 of 1024
65
Custom Capital Light Compounder
#5 of 213
81
Custom Deep Value Investing (Seth Klarman)
#283 of 820
51
Growth Price/Sales Ratio Focus (Ken Fisher)
#21 of 616
87
Custom Contrarian Investing (David Dreman)
#113 of 658
54
Value Defensive Investing (Benjamin Graham)
#460 of 708
20
Value Value Investing (Warren Buffett)
#41 of 195
52

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026